BAP1 tumour predisposition syndrome

Overview

BAP1 tumour predisposition syndrome is a rare inherited condition first formally described in 2011, though families with clustering of specific cancers were recognised earlier. The syndrome arises from pathogenic variants in the BAP1 gene and confers substantially elevated lifetime risks for several tumour types that are relatively uncommon in the general population. Affected individuals and families typically develop a characteristic pattern of tumours including uveal melanoma (a cancer of the eye), malignant mesothelioma (affecting the lining of the lungs or abdomen), cutaneous melanocytic BAP1-inactivated naevi (distinctive skin lesions), and clear cell renal cell carcinoma (a kidney cancer).

The exact prevalence of BAP1 tumour predisposition syndrome remains uncertain because the condition is rare and many families have not yet been identified through genetic testing. Evidence suggests that BAP1-related tumours often develop earlier than their sporadic counterparts, with some tumour types appearing in young adulthood. The syndrome can affect both males and females equally, and because it follows autosomal dominant inheritance, each child of an affected parent has a 50% chance of inheriting the pathogenic variant. Recognition of this syndrome has important implications for cancer surveillance and clinical management of affected individuals and their at-risk relatives.

Symptoms & clinical features

The clinical features of BAP1 tumour predisposition syndrome manifest primarily as an increased risk of developing specific tumour types, rather than as non-cancerous symptoms. Uveal melanoma, which develops in the pigmented layer of the eye, may cause vision changes, floaters, or loss of visual field, though some cases are detected during routine eye examinations before symptoms appear. Cutaneous melanocytic BAP1-inactivated naevi are distinctive skin lesions that often appear as pink, dome-shaped bumps, typically developing in adulthood and sometimes numbering in the dozens. These skin lesions are benign but serve as an important clinical marker for the syndrome.

Malignant mesothelioma, affecting the pleura (lung lining) or peritoneum (abdominal lining), typically causes symptoms such as shortness of breath, chest pain, abdominal swelling, or unexplained weight loss, though these manifestations often appear only when the tumour is advanced. Renal cell carcinoma may be asymptomatic in early stages and detected incidentally on imaging, or may present with blood in the urine, flank pain, or a palpable abdominal mass. Some individuals with BAP1 tumour predisposition syndrome develop additional tumour types including cholangiocarcinoma (bile duct cancer), basal cell carcinoma (a common skin cancer), or other malignancies. The age at which tumours develop varies considerably between individuals, even within the same family, and some pathogenic variant carriers may not develop cancer during their lifetime, though their risk remains elevated.

Video: Is cancer in your genes?

Affected organs

BAP1 tumour predisposition syndrome affects multiple organ systems, reflecting the widespread role of the BAP1 protein in cellular regulation. The eyes are frequently affected, with uveal melanoma representing one of the most characteristic tumours in this syndrome. The skin commonly shows melanocytic BAP1-inactivated naevi, which whilst benign, indicate the underlying genetic predisposition. The kidneys are a major site of tumour development, with clear cell renal cell carcinoma occurring in a substantial proportion of affected families.

The pleura and peritoneum (linings of the chest and abdominal cavities) are particularly significant sites, as malignant mesothelioma in individuals with BAP1 pathogenic variants can develop even without asbestos exposure, unlike sporadic mesothelioma which is strongly associated with occupational or environmental asbestos contact. The liver and bile ducts may be affected through cholangiocarcinoma development. Evidence suggests that other tissues including the breast, lung, and ovary may also show increased cancer risk, though the magnitude of these associations requires further research to establish definitively.

Multiple body systems

Systemic involvement

Cellular impact

Mechanism at cellular level

Risks & severity

The lifetime cancer risks in BAP1 tumour predisposition syndrome are substantially elevated compared to the general population, though precise risk estimates continue to evolve as more families are identified and followed over time. Evidence suggests that a high proportion of individuals carrying a pathogenic BAP1 variant will develop at least one associated tumour during their lifetime, though penetrance estimates vary and may be influenced by ascertainment bias in studies focusing on families with multiple affected members. Uveal melanoma represents one of the highest relative risks, with this rare eye cancer occurring far more frequently in variant carriers than in the general population.

Mesothelioma risk is markedly elevated even in the absence of asbestos exposure, and substantially higher in variant carriers who are also exposed to asbestos. Renal cell carcinoma occurs with increased frequency in carriers, often presenting earlier than sporadic cases. The severity of BAP1-associated tumours varies, though outcomes depend heavily on tumour type, stage at detection, and available treatments. Uveal melanoma can have serious consequences including vision loss and metastatic spread, whilst mesothelioma remains a particularly aggressive malignancy with limited treatment options. Age of onset for BAP1-related cancers is typically younger than sporadic cases, with some tumours developing in individuals in their 20s or 30s, though risk continues throughout life. The variable expression of the syndrome means that some variant carriers may remain unaffected or develop only benign skin lesions, whilst others experience multiple primary tumours.

Genetic causes

BAP1 tumour predisposition syndrome results from pathogenic variants in the BAP1 gene, located on chromosome 3. This gene encodes a deubiquitinase enzyme that strips ubiquitin molecules from specific target proteins. Ubiquitin is a small regulatory protein that cells attach to other proteins to mark them for various fates, including degradation or altered function. The BAP1 protein functions as part of several multi-protein complexes involved in critical cellular processes including gene expression regulation, DNA damage repair, cell cycle control, and cellular differentiation.

Under normal circumstances, BAP1 helps maintain genomic stability and regulates pathways that control cell growth and division. The protein plays a particularly important role in chromatin remodelling and histone modification, influencing which genes are active or silenced in cells. When pathogenic variants disrupt BAP1 function, cells lose these regulatory controls, potentially allowing uncontrolled proliferation and tumour development. Most pathogenic variants are loss-of-function changes that prevent production of functional BAP1 protein or substantially impair its enzymatic activity.

Tumour development in BAP1 syndrome typically follows a two-hit mechanism consistent with classical tumour suppressor gene behaviour: individuals inherit one non-functional copy of BAP1, and when the remaining functional copy is inactivated in a particular cell (through mutation or other mechanisms), that cell loses all BAP1 function, potentially initiating tumour formation. This explains why variant carriers have increased cancer risk but do not develop tumours in every tissue, as the second hit is a random somatic event. Evidence indicates that complete loss of BAP1 function particularly affects tissues where the protein plays critical regulatory roles, explaining the characteristic tumour spectrum seen in this syndrome.

• BAP1
  BRCA1 associated deubiquitinase 1
  The BAP1 gene provides instructions for a protein that acts as a deubiquitinase, playing a crucial role in cell growth, DNA repair, and tumour suppression.

Inheritance pattern

BAP1 tumour predisposition syndrome follows an autosomal dominant pattern of inheritance, meaning that inheriting a single pathogenic variant from one parent is sufficient to substantially increase cancer risk. Each child of an individual carrying a BAP1 pathogenic variant has a 50% (1 in 2) chance of inheriting that variant, regardless of the child's sex. Affected individuals inherit the pathogenic variant from a parent who either has the variant themselves or in whom it arose as a new (de novo) change. When multiple family members across generations develop the characteristic tumour types, this often indicates an inherited pathogenic variant being passed through the family.

The inheritance of a BAP1 pathogenic variant does not guarantee that cancer will definitely develop, nor does it predict which specific tumour types an individual might experience or at what age. The concept of reduced penetrance applies here - not all variant carriers develop cancer, and expression varies considerably even within families sharing the same pathogenic variant. This variability likely reflects the influence of other genetic factors, environmental exposures, and chance somatic events. For family planning and genetic counselling purposes, it is important to understand that an individual who has not inherited the familial pathogenic variant has cancer risks similar to the general population, whilst those who have inherited the variant face substantially elevated risks that warrant enhanced surveillance. Genetic counselling is strongly recommended for families affected by BAP1 tumour predisposition syndrome to discuss inheritance patterns, testing options for at-risk relatives, and implications for future generations.

Diagnosis & testing

Diagnosis of BAP1 tumour predisposition syndrome typically involves genetic testing to identify a pathogenic variant in the BAP1 gene, combined with clinical assessment of personal and family cancer history. Referral to clinical genetics services may occur when an individual presents with characteristic tumours (particularly uveal melanoma or mesothelioma at young age, or multiple BAP1-associated tumours), when distinctive cutaneous melanocytic BAP1-inactivated naevi are identified, or when family history reveals multiple relatives with the syndrome's characteristic cancer pattern. Within the NHS Genomic Medicine Service, testing for BAP1 is accessed through relevant PanelApp panels for cancer predisposition, with clinical genetics teams coordinating the testing pathway.

Genetic testing involves analysing DNA from a blood sample to identify pathogenic variants in the BAP1 gene, including sequence variants and gene deletions or duplications. When a tumour has already been identified, sometimes testing of the tumour tissue can reveal BAP1 loss that prompts consideration of germline (inherited) testing. Pre-test genetic counselling is essential to discuss the implications of testing, including possible results and their meaning for the individual and family members. Diagnosis may also incorporate clinical examination for the characteristic skin lesions, which when biopsied show distinctive histological features and loss of BAP1 protein expression. The NHS assigns relevant R-codes for inherited cancer susceptibility when referring for genomic testing, facilitating appropriate test selection and ensuring genetic counsellor involvement in the diagnostic pathway. Confirming a diagnosis allows for appropriate surveillance planning and cascade testing of at-risk family members.

Management & lifestyle

Management of BAP1 tumour predisposition syndrome centres on surveillance for the associated tumours, with the aim of detecting cancers at earlier, more treatable stages. Current surveillance protocols, whilst still evolving as evidence accumulates, typically include regular dermatological examinations to monitor for melanocytic naevi and skin cancers, ophthalmological assessments including detailed examination of the uveal tract to detect melanoma early, and renal imaging (usually MRI or ultrasound) to screen for kidney tumours. Some centres also recommend chest and abdominal imaging to monitor for mesothelioma, though the effectiveness of screening for this particular tumour type remains uncertain given its aggressive nature and diffuse growth pattern.

Surveillance intervals and specific protocols may vary between clinical genetics centres and should be tailored to individual and family history. Risk-reducing interventions are limited for most BAP1-associated tumours, though affected individuals are advised to avoid asbestos exposure entirely, given the synergistic effect between BAP1 variants and asbestos in mesothelioma development. Sun protection measures are recommended for skin health, following general cancer prevention guidance. When tumours are detected, treatment follows standard oncological approaches for that tumour type, though outcomes and treatment responses may differ somewhat from sporadic cases.

Within the NHS, individuals with confirmed BAP1 pathogenic variants are typically managed through clinical genetics services with coordination between genetic counsellors, oncologists, ophthalmologists, and other specialists as needed. Regular review allows surveillance protocols to be updated as new evidence emerges and as the individual's personal circumstances change. Genetic counselling provides ongoing support for affected individuals and facilitates predictive testing for at-risk relatives who may benefit from surveillance if found to carry the familial variant. Lifestyle factors including maintaining healthy weight, not smoking, and limiting alcohol intake align with general cancer prevention advice, though specific evidence for their impact in BAP1 syndrome is limited. Participation in research studies may be encouraged where available, as the rarity of this syndrome means that much remains to be learned about optimal management strategies.

UK care pathway

Within the NHS Genomic Medicine Service, individuals with suspected BAP1 tumour predisposition syndrome are referred to regional clinical genetics services, typically through their GP or a specialist who has identified concerning features such as characteristic tumours or suggestive family history. The referral initiates a pathway involving genetic counselling to discuss the indication for testing, family history assessment, and consent for genomic testing. BAP1 testing is included in relevant PanelApp panels for cancer predisposition syndromes, with the specific panel selected based on clinical presentation. R-codes for hereditary cancer susceptibility facilitate appropriate test ordering within the NHS genomic testing infrastructure.

Once a pathogenic variant is confirmed, the clinical genetics team coordinates ongoing care, including establishing a surveillance plan, providing information and support, and offering predictive testing to at-risk relatives. Genetic counsellors play a central role throughout this pathway, ensuring individuals understand their results, implications for family members, and available management options. Multidisciplinary team input may include oncologists, ophthalmologists, dermatologists, and radiologists contributing to surveillance protocols. NHS England guidance on genetic testing for cancer predisposition continues to evolve, and individuals with BAP1 tumour predisposition syndrome may be offered participation in research studies or national registries that aim to improve understanding of the condition and refine management recommendations.

Related conditions

Several other inherited cancer predisposition syndromes share overlapping features with BAP1 tumour predisposition syndrome, though each has a distinct genetic cause and tumour spectrum. Lynch syndrome and other hereditary cancer syndromes may present with multiple primary cancers in a family, necessitating careful genetic evaluation to determine the underlying cause. Familial atypical multiple mole melanoma (FAMMM) syndrome, caused by pathogenic variants in CDKN2A, shares the feature of increased melanoma risk and distinctive skin lesions, though FAMMM primarily affects cutaneous rather than uveal melanoma. Von Hippel-Lindau syndrome includes renal cell carcinoma in its tumour spectrum but is associated with clear cell renal carcinomas alongside other characteristic features including retinal and central nervous system haemangioblastomas.

Hereditary renal cell carcinoma syndromes caused by pathogenic variants in genes such as FH, FLCN, or MET may present with kidney tumours and require differentiation from BAP1 syndrome through genetic testing and assessment of other clinical features. Individuals with mesothelioma and no asbestos exposure history warrant consideration of BAP1 testing, as sporadic mesothelioma without environmental exposure is uncommon. The presence of multiple melanocytic naevi with characteristic histology, particularly when combined with personal or family history of uveal melanoma or mesothelioma, should prompt specific consideration of BAP1 tumour predisposition syndrome rather than other melanoma syndromes. Accurate genetic diagnosis is essential because surveillance protocols and cancer risks differ substantially between these various inherited cancer conditions.

Frequently asked questions

References

1. Jager MJ, Shields CL, Cebulla CM. Uveal melanoma. Nature reviews. Disease primers. 2020. PMID: 32273508
2. Robinson P, Rajan N. BAP1-tumour predisposition syndrome. The British journal of dermatology. 2026. PMID: 42384974
3. Lalloo F, Kulkarni A, Chau C. Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome. European journal of human genetics : EJHG. 2023. PMID: 37607989
4. Drabent P, Touat M, Benusiglio PR. A Specific Methylation Class Identifies BAP1-Deficient Meningiomas, Including Meningeal Tumours With Poorly Differentiated Nonrhabdoid Histology. Neuropathology and applied neurobiology. 2025. PMID: 41024725
5. Pandithan D, Klebe S, McKavanagh G. BAP1 Tumour Predisposition Syndrome Due to Whole BAP1 Gene Deletion. Case reports in genetics. 2022. PMID: 36148247
6. Vimercati L, Cavone D, Fortarezza F. Case report: Mesothelioma and BAP1 tumor predisposition syndrome: Implications for public health. Frontiers in oncology. 2022. PMID: 35992853
7. Satolli F, de Felici del Giudice MB, Bertolani M. BAP1 Tumour Predisposition Syndrome: A New Mutation in One Family. Acta dermato-venereologica. 2019. PMID: 31314123
8. El Jiar M, Huybrechts S, Pissaloux D. Childhood melanoma ex-blue naevus leading to the identification of a BAP1 tumour predisposition syndrome. Pathology. 2025. PMID: 40744778